BioGaia AB (publ) (FRA:BGLA)

Market Cap	1.09B +5.4%
Revenue (ttm)	142.13M +8.1%
Net Income	30.75M -5.3%
EPS	0.30 -5.4%
Shares Out	n/a
PE Ratio	35.33
Forward PE	28.21
Dividend	0.63 (6.16%)
Ex-Dividend Date	May 8, 2025

Volume	n/a
Average Volume	50
Open	10.65
Previous Close	10.27
Day's Range	10.65 - 10.65
52-Week Range	8.38 - 10.84
Beta	n/a
RSI	57.88
Earnings Date	Jul 17, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 242
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BGLA

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK